Developer docs
API playgroundTry for free, no card

Search company profiles

Perlara

Full company profile

uuid0002skc

Namestring
Perlara
Legal namestring
Perlara, PBC
Websiteurl
perlara.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Perlara, PBC is a precision drug discovery company founded in 2014 and headquartered in South San Francisco that develops therapies for ultra-rare inherited metabolic diseases (IMDs). It operates a yeast-first, patient-partnered drug discovery platform called REMIT (Repurposing with Engineered Models of Inherited metabolic disease Targets), which uses humanized yeast disease avatars — primarily Yarrowia lipolytica and Saccharomyces cerevisiae — to screen a standardized library of 8,384 repurposable compounds (sourced from TargetMol) across 34 IMD models covering congenital disorders of glycosylation (PMM2, ALG11, DHDDS), mitochondrial disorders (electron transport chain complexes CI–CV, SURF1, ECHS1), GPI-anchor disorders (PIGN, PIGW), tRNA-synthetase syndromes (NARS1, FARS2, MTAARS2), and others (FOXG1, ADSL). Hits are validated in patient-derived cells before advancing through IND-enabling and registrational trials. The company's flagship program, Maggie's Pearl, advanced epalrestat — a Japanese aldose-reductase inhibitor approved for diabetic neuropathy — from a parent-initiated N-of-1 study to a 38-patient Phase III registrational trial at Mayo Clinic Minnesota in under three years for less than $5M in patient-foundation capital.

All screening data is published through a public data portal (dashboard.perlara.com) before IP filing, an unusual transparency choice that doubles as both credibility-building content and a published working notebook via the Cure Odysseys Substack. The company currently runs 12 active programs with a stated ambition to scale to approximately 600 over the next decade.

Perlara's revenue model is multi-stream but project-based: (1) NIH and SBIR grant funding — most recently a $1.7M Direct-to-Phase-II SBIR from NIH NCATS in November 2025 for inherited mitochondrial disease platform development, (2) patient-foundation capital funding individual PerlQuest/Cure Odyssey programs, (3) out-licensing of IND-enabling-ready assets to pharma and biotech partners (with patient-foundation rights and Cure Odysseys narration access retained), and (4) joint ventures such as Maggie's Pearl. Customer segments are rare disease families and patient foundations (primary), academic research groups (primary), and pharma/biotech licensing partners (secondary). The company is a founder-led Public Benefit Corporation under CEO Ethan Perlstein, with a lean core team of approximately six scientific, clinical, and operations members supported by a decentralized wet lab.

Short descriptiontext

Perlara, PBC is a precision drug discovery company that uses humanized yeast disease avatars to screen repurposable compounds for inherited metabolic diseases. It partners with patient foundations and academic centers, and advanced its flagship PMM2-CDG program to Phase III under $5M.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease drug discovery, yeast-based drug repurposing, inherited metabolic diseases, patient-partnered therapeutics, IND-enabling asset licensing
Industry3 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotech Drug Discovery
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1NIH SBIR Grants
TypeLicensing Royalties
Description

Direct-to-Phase-II SBIR grant from NIH NCATS awarded in November 2025 for $1.7M to develop yeast-based drug discovery platforms for inherited mitochondrial diseases, covering electron transport chain models.

einpresswire.com
2Patient-Foundation Funding
TypeLicensing Royalties
Description

Funding from patient foundations and families (e.g., Maggie's PMM2-CDG Cure, Cure Sanfilippo Foundation, Multiple Sulfatase Deficiency Action Foundation) to support specific PerlQuest/Cure Odyssey programs. Patient-foundation capital supported the Maggie's Pearl Phase III for under $5M.

archive.perlara.com
3Licensing / Out-licensing
TypeLicensing Royalties
Description

Out-licensing of IND-enabling-ready assets to pharma and biotech partners who can advance development and commercialization. Perlara retains patient-foundation rights and Cure Odysseys narration access.

perlara.com
4Maggie's Pearl Joint Venture
TypeLicensing Royalties
Description

Joint venture with a pioneer family, Maggie's Pearl, to develop and commercialize the epalrestat program for PMM2-CDG. Represents the first co-developed asset from the platform.

archive2.perlara.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1REMIT
Description

Repurposing with Engineered Models of Inherited metabolic disease Targets — a four-stage drug discovery engine: build yeast avatar, screen library, validate in patient cells, advance through IND-enabling and trials.

perlara.com
+3 more records
Core offering1 text field

Perlara is a full-stack drug discovery and development company for inherited metabolic diseases. It builds humanized yeast disease avatars, screens a standardized 8,384-compound repurposing library, validates hits in patient-derived cells, advances programs through IND-enabling studies, and out-licenses or co-develops assets (e.g., Maggie's Pearl epalrestat for PMM2-CDG) with pharma, biotech, and patient foundations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase III reached in under 3 years for under $5M patient-foundation capital (Maggie's Pearl/epalrestat for PMM2-CDG)
+3 more records
Product overview1 text field

Perlara is a full-stack drug discovery and development company operating through an integrated platform centered on the REMIT Engine. The core offering combines yeast-based disease modeling with patient partnership programs, including the flagship Maggie's Pearl (epalrestat for PMM2-CDG, now in Phase III). Supporting infrastructure includes the Data Portal for public screening data access, Cure Odysseys Substack as the working notebook, and the Pipeline tracking active programs across CDGs, mitochondrial disorders, GPI-anchor defects, and tRNA-synthetase syndromes. Historical offerings from the Perlara 2.0 era include Guided Cures consulting services.

Product and service6 records
1REMIT Engine
CategoryDrug Discovery Platform
Description

Repurposing with Engineered Models of Inherited metabolic disease Targets (REMIT): a four-stage drug discovery engine — build the yeast avatar, screen a standardized library, validate in patient cells, advance through IND-enabling and trials. Used by Perlara's scientific team and partners to advance rare metabolic disease programs.

2Maggie's Pearl (epalrestat for PMM2-CDG)
CategoryClinical Development Program
Description

Flagship co-developed asset and joint venture with a pioneer family; a parent-initiated N-of-1 study of epalrestat (a Japanese diabetic-neuropathy drug) for PMM2-CDG that reached a 38-patient Phase III at Mayo Clinic Minnesota in under three years for less than $5M in patient-foundation capital.

3Public Data Portal
CategoryDrug Discovery Platform
Description

Public interactive dashboard providing access to Perlara's yeast screening data across 34 IMD models and 8,384 TargetMol compounds, with gene/disease overview, compound x gene heatmaps, compound explorer, dual-condition pairs, and per-compound fingerprints. De-identified data is published publicly before IP filing.

4Cure Odysseys Substack
CategoryDrug Discovery Platform
Description

Public Substack notebook narrating each Perlara program in real time, serving as both a working lab notebook and a community engagement channel documenting the family, yeast model, hit list, N-of-1 protocol, and what fails.

5Guided Cures™ Consulting Services
CategoryConsulting Service
Description

Modality-agnostic virtual consulting and model-agnostic drug repurposing services offered during the Perlara 2.0 era to families and scientists seeking to advance treatments and cures for rare diseases.

6IMD Pipeline (12 active programs targeting CDGs, mitochondrial disorders, GPI-anchor defects, tRNA-synthetase syndromes)
CategoryClinical Development Program
Description

Active inherited metabolic disease programs covering congenital disorders of glycosylation (PMM2, ALG11, DHDDS, GMPPA), mitochondrial electron transport chain disorders (SURF1, ECHS1), GPI-anchor disorders (PIGN, PIGW), tRNA-synthetase syndromes (NARS1, FARS2, MTAARS2), and other ultra-rare metabolic biology; out-licensed or co-developed with patient foundations, academic medical centers, and pharma partners.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1CDG UK
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Supporting an international clinical trial for DHDDS-related congenital neurodegenerative disease involving 12 patients over one year, using patient-derived mini-brain organoids and nicotinamide mononucleotide (NMN) as a potential therapeutic. Some families have already reported improvements from NMN supplementation.

bioengineer.org
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Collaboration on GNAO1 neurodevelopmental disorder drug discovery using patient-derived yeast avatars. Development of variant-specific GNAO1 models (including A221D) in collaboration with the Undiagnosed Diseases Network and Harvard Medical School.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Leigh Syndrome PerlQuest partnership with Radical Investments. A new treatment for Leigh syndrome is noted to have broader implications for aging, sports medicine, traumatic brain injury, and neurodegeneration.

4Rambam Medical Center
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

APOL1 kidney disease PerlQuest partnership with Rambam Medical Center. APOL1 genetic risk affects approximately 100 million people worldwide.

archive.perlara.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

PerlQuest exploration for Phelan-McDermid Syndrome (PMS), including engagement at the 2018 International Family Conference. PMS involves SHANK3 and related neurodevelopmental pathways potentially addressable through Perlara's platform.

6Cedars-Sinai Medical Center
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Parallel collaboration with Cedars-Sinai Medical Center established through the Mission: Cure partnership. Small molecules discovered in Perlara's yeast screens are advanced directly to testing in an artificial pancreas system using cells derived from pancreatitis patients.

archive.perlara.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Collaboration with Novartis focused on lysosomal diseases, including developing worm and fly models for Multiple Sulfatase Deficiency (ML4) and Niemann-Pick Type C (NPC) using a curated bioactive collection ('MoA Box') for high-throughput screening.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Collaboration on screening platform for glycogen storage diseases including Cori Disease (GSD III) and Pompe Disease (GSD II). The Warren Center provides academic infrastructure for fly model development and drug screening for these conditions.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Pancreatitis PerlQuest partnership to develop yeast models of 27 CFTR patient variants and screen for small molecule therapeutics. Mission: Cure also established a parallel collaboration with Cedars-Sinai Medical Center so that yeast-discovered hits can be advanced to testing in patient-derived cell systems.

10Multiple Sulfatase Deficiency Action Foundation
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

MSD PerlQuest partnership for Multiple Sulfatase Deficiency, including fly model development and phenotypic screening. Built as part of the broader Novartis lysosomal diseases collaboration.

archive.perlara.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

MPSIII PerlQuest partnership for Sanfilippo syndrome (MPSIIIA and MPSIIIB), involving nematode and fly disease models and compound screening programs.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

PerlQuest partnership for Niemann-Pick Type A. Perlara identified tool compounds, repurposable drugs, and novel chemotypes that rescue worm and fly disease models.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

NGLY1 PerlQuest partnership focused on yeast and fly disease models and drug repurposing screens for NGLY1 Deficiency. The partnership was among Perlara's earliest patient foundation collaborations.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Flagship parent-initiated N-of-1 study that became a joint venture and the template for the Perlara 3.0 model. Epalrestat (a Japanese diabetic-neuropathy drug) advanced from compassionate use to a 38-patient Phase III at Mayo Clinic Minnesota in under 3 years for under $5M. The first Cure Odyssey and first joint venture with a pioneer family.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Rare disease biopharmaceutical company with approved therapies and pipeline focused on metabolic disorders, including lysosomal storage diseases that overlap with Perlara's glycosylation and GPI-anchor programs. Note: Travere was an early Perlara investor (2014), suggesting historic strategic alignment.

TypeDirect peer
Description

Genetic disease drug discovery company focused on translating insights from genetic variation into oral small molecule therapies. Shares Perlara's genetic-disease-first approach and patient-foundation partnership orientation, though Maze focuses on common variant-informed targets rather than ultra-rare inherited metabolic disease.

TypeBroad incumbent
Description

Established rare disease biopharmaceutical company with multiple approved enzyme replacement therapies and small molecule drugs for inherited metabolic disorders including CLN2, MPS, and PKU. Represents the scaled commercial endpoint of the patient-foundation-to-registrational-trial model Perlara aspires to.

TypeBroad incumbent
Description

AstraZeneca's rare disease unit focused on rare metabolic and hematologic disorders, including approved therapies for lysosomal storage diseases and hypophosphatasia. A likely strategic acquirer or licensing partner for Perlara's IND-ready metabolic disease assets at scale.

TypeBroad incumbent
Description

Genetic disease-focused biopharmaceutical company developing therapeutics for rare and underserved conditions. Overlap with Perlara's inherited metabolic disease focus (e.g., metabolic disorders), but BridgeBio operates at significantly larger scale with broad pipeline across multiple rare disease modalities.

TypeBroad incumbent
Description

Clinical-stage biopharmaceutical company focused exclusively on rare and ultra-rare genetic diseases, including multiple inherited metabolic disorders. Comparable patient-foundation relationships and ultra-rare focus, but operates as a full integrated biotech with approved products versus Perlara's platform-discovery model.

7Perlara PBC itself lists a University of Notre Dame partnership on Pompe/GSD III
TypeOthers
Description

Academic rare disease screening centers and contract research organizations supporting patient-derived disease modeling and drug screening represent adjacent ecosystem partners rather than direct competitors, but compete for the same foundation funding and patient-foundation engagement relationships.

TypeDirect peer
Description

Tech-enabled drug discovery platform combining high-throughput biology with machine learning. Like Perlara, it pursues repurposing and novel targets using model organism data, though at much larger scale and across broader therapeutic areas; their shared 'biology-first, platform-native' ethos makes them a direct comparator.

9Pompe Therapeutics (Amicus)
TypeBroad incumbent
Description

Rare disease biotech with approved and pipeline therapies for inherited metabolic disorders including Fabry disease and Pompe disease (GSD II), which Perlara also has a screening collaboration on with Notre Dame. Strong comparability on disease area, though Amicus is significantly larger and integrated.

10Cydan Development
TypeEmerging player
Description

Orphan drug accelerator that identifies and de-risks therapeutic candidates for rare diseases before spinning out standalone companies. Conceptually similar to Perlara's patient-foundation incubation model, though Cydan operates across modalities and at venture-scale rather than yeast-based discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Perlara

Biotech Drug Discoveryperlara.com

Perlara, PBC is a precision drug discovery company that uses humanized yeast disease avatars to screen repurposable compounds for inherited metabolic diseases. It partners with patient foundations and academic centers, and advanced its flagship PMM2-CDG program to Phase III under $5M.

What Perlara does

Perlara, PBC is a precision drug discovery company founded in 2014 and headquartered in South San Francisco that develops therapies for ultra-rare inherited metabolic diseases (IMDs). It operates a yeast-first, patient-partnered drug discovery platform called REMIT (Repurposing with Engineered Models of Inherited metabolic disease Targets), which uses humanized yeast disease avatars — primarily Yarrowia lipolytica and Saccharomyces cerevisiae — to screen a standardized library of 8,384 repurposable compounds (sourced from TargetMol) across 34 IMD models covering congenital disorders of glycosylation (PMM2, ALG11, DHDDS), mitochondrial disorders (electron transport chain complexes CI–CV, SURF1, ECHS1), GPI-anchor disorders (PIGN, PIGW), tRNA-synthetase syndromes (NARS1, FARS2, MTAARS2), and others (FOXG1, ADSL). Hits are validated in patient-derived cells before advancing through IND-enabling and registrational trials. The company's flagship program, Maggie's Pearl, advanced epalrestat — a Japanese aldose-reductase inhibitor approved for diabetic neuropathy — from a parent-initiated N-of-1 study to a 38-patient Phase III registrational trial at Mayo Clinic Minnesota in under three years for less than $5M in patient-foundation capital.

All screening data is published through a public data portal (dashboard.perlara.com) before IP filing, an unusual transparency choice that doubles as both credibility-building content and a published working notebook via the Cure Odysseys Substack. The company currently runs 12 active programs with a stated ambition to scale to approximately 600 over the next decade.

Perlara's revenue model is multi-stream but project-based: (1) NIH and SBIR grant funding — most recently a $1.7M Direct-to-Phase-II SBIR from NIH NCATS in November 2025 for inherited mitochondrial disease platform development, (2) patient-foundation capital funding individual PerlQuest/Cure Odyssey programs, (3) out-licensing of IND-enabling-ready assets to pharma and biotech partners (with patient-foundation rights and Cure Odysseys narration access retained), and (4) joint ventures such as Maggie's Pearl. Customer segments are rare disease families and patient foundations (primary), academic research groups (primary), and pharma/biotech licensing partners (secondary). The company is a founder-led Public Benefit Corporation under CEO Ethan Perlstein, with a lean core team of approximately six scientific, clinical, and operations members supported by a decentralized wet lab.

Perlara firmographics

Firmographics
Name
Perlara
Legal name
Perlara, PBC
Website
https://perlara.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Perlara, PBC is a precision drug discovery company that uses humanized yeast disease avatars to screen repurposable compounds for inherited metabolic diseases. It partners with patient foundations and academic centers, and advanced its flagship PMM2-CDG program to Phase III under $5M.
Ownership category
akta.pro rank

Perlara industry classification

Industry
Product category
Biotech Drug Discovery
NAICS
Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Rare disease drug discovery
  • Yeast-based drug repurposing
  • Inherited metabolic diseases
  • Patient-partnered therapeutics
  • IND-enabling asset licensing

Where Perlara is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Perlara business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. NIH SBIR Grants: Direct-to-Phase-II SBIR grant from NIH NCATS awarded in November 2025 for $1.7M to develop yeast-based drug discovery platforms for inherited mitochondrial diseases, covering electron transport chain models.
  2. Patient-Foundation Funding: Funding from patient foundations and families (e.g., Maggie's PMM2-CDG Cure, Cure Sanfilippo Foundation, Multiple Sulfatase Deficiency Action Foundation) to support specific PerlQuest/Cure Odyssey programs. Patient-foundation capital supported the Maggie's Pearl Phase III for under $5M.
  3. Licensing / Out-licensing: Out-licensing of IND-enabling-ready assets to pharma and biotech partners who can advance development and commercialization. Perlara retains patient-foundation rights and Cure Odysseys narration access.
  4. Maggie's Pearl Joint Venture: Joint venture with a pioneer family, Maggie's Pearl, to develop and commercialize the epalrestat program for PMM2-CDG. Represents the first co-developed asset from the platform.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Perlara product offering

Product offering

Core offering

Perlara is a full-stack drug discovery and development company for inherited metabolic diseases. It builds humanized yeast disease avatars, screens a standardized 8,384-compound repurposing library, validates hits in patient-derived cells, advances programs through IND-enabling studies, and out-licenses or co-develops assets (e.g., Maggie's Pearl epalrestat for PMM2-CDG) with pharma, biotech, and patient foundations.

Product overview

Perlara is a full-stack drug discovery and development company operating through an integrated platform centered on the REMIT Engine. The core offering combines yeast-based disease modeling with patient partnership programs, including the flagship Maggie's Pearl (epalrestat for PMM2-CDG, now in Phase III). Supporting infrastructure includes the Data Portal for public screening data access, Cure Odysseys Substack as the working notebook, and the Pipeline tracking active programs across CDGs, mitochondrial disorders, GPI-anchor defects, and tRNA-synthetase syndromes. Historical offerings from the Perlara 2.0 era include Guided Cures consulting services.

Differentiator

Problem solved

Functional benefit

Brands

  • REMIT: Repurposing with Engineered Models of Inherited metabolic disease Targets — a four-stage drug discovery engine: build yeast avatar, screen library, validate in patient cells, advance through IND-enabling and trials.
  • Cure Odysseys
  • Guided Cures™
  • PerlQuests

Products and services

  • REMIT Engine Repurposing with Engineered Models of Inherited metabolic disease Targets (REMIT): a four-stage drug discovery engine — build the yeast avatar, screen a standardized library, validate in patient cells, advance through IND-enabling and trials. Used by Perlara's scientific team and partners to advance rare metabolic disease programs.
  • Maggie's Pearl (epalrestat for PMM2-CDG) Flagship co-developed asset and joint venture with a pioneer family; a parent-initiated N-of-1 study of epalrestat (a Japanese diabetic-neuropathy drug) for PMM2-CDG that reached a 38-patient Phase III at Mayo Clinic Minnesota in under three years for less than $5M in patient-foundation capital.
  • Public Data Portal Public interactive dashboard providing access to Perlara's yeast screening data across 34 IMD models and 8,384 TargetMol compounds, with gene/disease overview, compound x gene heatmaps, compound explorer, dual-condition pairs, and per-compound fingerprints. De-identified data is published publicly before IP filing.
  • Cure Odysseys Substack Public Substack notebook narrating each Perlara program in real time, serving as both a working lab notebook and a community engagement channel documenting the family, yeast model, hit list, N-of-1 protocol, and what fails.
  • Guided Cures™ Consulting Services Modality-agnostic virtual consulting and model-agnostic drug repurposing services offered during the Perlara 2.0 era to families and scientists seeking to advance treatments and cures for rare diseases.
  • IMD Pipeline (12 active programs targeting CDGs, mitochondrial disorders, GPI-anchor defects, tRNA-synthetase syndromes) Active inherited metabolic disease programs covering congenital disorders of glycosylation (PMM2, ALG11, DHDDS, GMPPA), mitochondrial electron transport chain disorders (SURF1, ECHS1), GPI-anchor disorders (PIGN, PIGW), tRNA-synthetase syndromes (NARS1, FARS2, MTAARS2), and other ultra-rare metabolic biology; out-licensed or co-developed with patient foundations, academic medical centers, and pharma partners.

Quantifiable outcome

  • Phase III reached in under 3 years for under $5M patient-foundation capital (Maggie's Pearl/epalrestat for PMM2-CDG)
  • +3 more outcomes

Companies that use Perlara

Customer profile

Named customers12 records

Segments3 records

Ideal customer profiles3 records

Perlara technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Perlara partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered major, minor and flagship.

  • CDG UKmajorStrategic or Co-development Partner · 1 January 2026Supporting an international clinical trial for DHDDS-related congenital neurodegenerative disease involving 12 patients over one year, using patient-derived mini-brain organoids and nicotinamide mononucleotide (NMN) as a potential therapeutic. Some families have already reported improvements from NMN supplementation.
  • Harvard / Undiagnosed Diseases NetworkmajorStrategic or Co-development Partner · 1 January 2018Collaboration on GNAO1 neurodevelopmental disorder drug discovery using patient-derived yeast avatars. Development of variant-specific GNAO1 models (including A221D) in collaboration with the Undiagnosed Diseases Network and Harvard Medical School.
  • Radical InvestmentsmajorStrategic or Co-development Partner · 1 January 2018Leigh Syndrome PerlQuest partnership with Radical Investments. A new treatment for Leigh syndrome is noted to have broader implications for aging, sports medicine, traumatic brain injury, and neurodegeneration.
  • Rambam Medical CentermajorStrategic or Co-development Partner · 1 January 2018APOL1 kidney disease PerlQuest partnership with Rambam Medical Center. APOL1 genetic risk affects approximately 100 million people worldwide.
  • Phelan-McDermid Syndrome FoundationminorStrategic or Co-development Partner · 1 January 2018PerlQuest exploration for Phelan-McDermid Syndrome (PMS), including engagement at the 2018 International Family Conference. PMS involves SHANK3 and related neurodevelopmental pathways potentially addressable through Perlara's platform.
  • Cedars-Sinai Medical CentermajorStrategic or Co-development Partner · 1 January 2018Parallel collaboration with Cedars-Sinai Medical Center established through the Mission: Cure partnership. Small molecules discovered in Perlara's yeast screens are advanced directly to testing in an artificial pancreas system using cells derived from pancreatitis patients.
  • NovartismajorStrategic or Co-development Partner · 1 January 2017Collaboration with Novartis focused on lysosomal diseases, including developing worm and fly models for Multiple Sulfatase Deficiency (ML4) and Niemann-Pick Type C (NPC) using a curated bioactive collection ('MoA Box') for high-throughput screening.
  • University of Notre Dame (Warren Center for Drug Discovery)majorStrategic or Co-development Partner · 1 January 2017Collaboration on screening platform for glycogen storage diseases including Cori Disease (GSD III) and Pompe Disease (GSD II). The Warren Center provides academic infrastructure for fly model development and drug screening for these conditions.
  • Mission: CuremajorStrategic or Co-development Partner · 1 January 2017Pancreatitis PerlQuest partnership to develop yeast models of 27 CFTR patient variants and screen for small molecule therapeutics. Mission: Cure also established a parallel collaboration with Cedars-Sinai Medical Center so that yeast-discovered hits can be advanced to testing in patient-derived cell systems.
  • Multiple Sulfatase Deficiency Action FoundationmajorStrategic or Co-development Partner · 1 January 2017MSD PerlQuest partnership for Multiple Sulfatase Deficiency, including fly model development and phenotypic screening. Built as part of the broader Novartis lysosomal diseases collaboration.
  • Cure Sanfilippo FoundationmajorStrategic or Co-development Partner · 1 January 2017MPSIII PerlQuest partnership for Sanfilippo syndrome (MPSIIIA and MPSIIIB), involving nematode and fly disease models and compound screening programs.
  • Wylder Nation FoundationmajorStrategic or Co-development Partner · 1 January 2017PerlQuest partnership for Niemann-Pick Type A. Perlara identified tool compounds, repurposable drugs, and novel chemotypes that rescue worm and fly disease models.
  • Grace Science FoundationmajorStrategic or Co-development Partner · 1 January 2016NGLY1 PerlQuest partnership focused on yeast and fly disease models and drug repurposing screens for NGLY1 Deficiency. The partnership was among Perlara's earliest patient foundation collaborations.
  • Maggie's PMM2-CDG Cure (Maggie's Pearl)flagshipStrategic or Co-development PartnerFlagship parent-initiated N-of-1 study that became a joint venture and the template for the Perlara 3.0 model. Epalrestat (a Japanese diabetic-neuropathy drug) advanced from compassionate use to a 38-patient Phase III at Mayo Clinic Minnesota in under 3 years for under $5M. The first Cure Odyssey and first joint venture with a pioneer family.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Perlara competitors and assessment

Company assessment

Broad incumbents

  • Travere Therapeutics: Rare disease biopharmaceutical company with approved therapies and pipeline focused on metabolic disorders, including lysosomal storage diseases that overlap with Perlara's glycosylation and GPI-anchor programs. Note: Travere was an early Perlara investor (2014), suggesting historic strategic alignment.
  • BioMarin Pharmaceutical: Established rare disease biopharmaceutical company with multiple approved enzyme replacement therapies and small molecule drugs for inherited metabolic disorders including CLN2, MPS, and PKU. Represents the scaled commercial endpoint of the patient-foundation-to-registrational-trial model Perlara aspires to.
  • Alexion / AstraZeneca Rare Disease: AstraZeneca's rare disease unit focused on rare metabolic and hematologic disorders, including approved therapies for lysosomal storage diseases and hypophosphatasia. A likely strategic acquirer or licensing partner for Perlara's IND-ready metabolic disease assets at scale.
  • BridgeBio Pharma: Genetic disease-focused biopharmaceutical company developing therapeutics for rare and underserved conditions. Overlap with Perlara's inherited metabolic disease focus (e.g., metabolic disorders), but BridgeBio operates at significantly larger scale with broad pipeline across multiple rare disease modalities.
  • Ultragenyx Pharmaceutical: Clinical-stage biopharmaceutical company focused exclusively on rare and ultra-rare genetic diseases, including multiple inherited metabolic disorders. Comparable patient-foundation relationships and ultra-rare focus, but operates as a full integrated biotech with approved products versus Perlara's platform-discovery model.
  • Pompe Therapeutics (Amicus): Rare disease biotech with approved and pipeline therapies for inherited metabolic disorders including Fabry disease and Pompe disease (GSD II), which Perlara also has a screening collaboration on with Notre Dame. Strong comparability on disease area, though Amicus is significantly larger and integrated.

Direct peers

  • Maze Therapeutics: Genetic disease drug discovery company focused on translating insights from genetic variation into oral small molecule therapies. Shares Perlara's genetic-disease-first approach and patient-foundation partnership orientation, though Maze focuses on common variant-informed targets rather than ultra-rare inherited metabolic disease.
  • Recursion Pharmaceuticals: Tech-enabled drug discovery platform combining high-throughput biology with machine learning. Like Perlara, it pursues repurposing and novel targets using model organism data, though at much larger scale and across broader therapeutic areas; their shared 'biology-first, platform-native' ethos makes them a direct comparator.

Others

  • Perlara PBC itself lists a University of Notre Dame partnership on Pompe/GSD III: Academic rare disease screening centers and contract research organizations supporting patient-derived disease modeling and drug screening represent adjacent ecosystem partners rather than direct competitors, but compete for the same foundation funding and patient-foundation engagement relationships.

Emerging players

  • Cydan Development: Orphan drug accelerator that identifies and de-risks therapeutic candidates for rare diseases before spinning out standalone companies. Conceptually similar to Perlara's patient-foundation incubation model, though Cydan operates across modalities and at venture-scale rather than yeast-based discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Perlara social profiles

Digital presence

Perlara financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Perlara leadership team

Management profile

Number of profiles

Profiles6 records

Perlara funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Perlara M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perlara

What does Perlara do?

Perlara is a full-stack drug discovery and development company for inherited metabolic diseases. It builds humanized yeast disease avatars, screens a standardized 8,384-compound repurposing library, validates hits in patient-derived cells, advances programs through IND-enabling studies, and out-licenses or co-develops assets (e.g., Maggie's Pearl epalrestat for PMM2-CDG) with pharma, biotech, and patient foundations.

Is Perlara a public or private company?

Perlara is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Perlara founded?

Perlara was founded in 2014. It employs 11 to 50 people.

Where is Perlara based?

Perlara is headquartered in San Francisco, United States, in the North America region.

How does Perlara make money?

Four revenue lines are on record. NIH SBIR Grants are the primary driver. The others are patient-Foundation Funding, licensing / Out-licensing and maggie's Pearl Joint Venture.

Who are Perlara's main competitors?

Broad incumbents on record are Travere Therapeutics, BioMarin Pharmaceutical, Alexion / AstraZeneca Rare Disease, BridgeBio Pharma, Ultragenyx Pharmaceutical and Pompe Therapeutics (Amicus). Direct peers are Maze Therapeutics and Recursion Pharmaceuticals. Perlara PBC itself lists a University of Notre Dame partnership on Pompe/GSD III is listed as an others. Cydan Development is listed as an emerging player.

Does Perlara have an API?

No public API is recorded for Perlara.

What industry is Perlara in?

Perlara's product category is Biotech Drug Discovery. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 5417 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalResearchers map rare DHDDS disease mechanism using lab-grown mini brainsResearchers using patient-derived mini-brains mapped the DHDDS disease mechanism and found that vitamin B3 (NMN) slows progression. The study, presented at the European Society of Human Genetics conference, showed NMN improved symptoms in patients, and an international trial is planned.EIN PresswirePerlara PBC awarded $1.7M SBIR grant to fund yeast-powered drug discovery for mitochondrial diseasesPerlara PBC, a biotech public benefit corporation focused on inherited metabolic diseases, has been awarded a $1.7 million Direct-to-Phase-2 SBIR grant (REMIT) to expand its yeast-powered drug discovery platform for mitochondrial diseases. The platform uses Yarrowia lipolytica yeast to model electron transport chain deficiencies (Complexes I-V), with the goal of identifying rational mitochondrial cocktail treatments that could benefit patients across multiple disease genotypes. The company stated this funding marks a turning point in its 11-year history, enabling a strategic shift from drug repurposing services toward developing novel medicines for inherited metabolic diseases.PR NewswireMaggie's Pearl inicia un ensayo clínico de fase III para el tratamiento de pacientes con PMM2-CDGMaggie's Pearl LLC, a joint venture between Perlara, Maggie's Cure, and Mayo Clinic, has initiated a Phase III clinical trial to evaluate oral epalrestat therapy versus placebo for pediatric patients with PMM2-CDG, a rare congenital glycosylation disorder. The trial received FDA approval in December 2021 and is currently actively recruiting, with the first two subjects dosed in December 2022. The study aims to assess safety, tolerability, metabolic improvement, and clinical outcomes in 40 patients, representing a potential first treatment option for the approximately 1,000 known patients worldwide with this genetic condition.PR NewswirePMM2-CDG患者的III期临床试验启动Maggie's Pearl, a joint venture between Perlara, Maggie's Cure, and Mayo Clinic, has launched a Phase III clinical trial to evaluate oral epalrestat therapy in 40 pediatric patients with PMM2-CDG, a rare genetic disorder affecting glycosylation. The trial, managed by Mayo Clinic and approved by the FDA in December 2021, is currently recruiting subjects, with the first two patients dosed in December 2022. The primary goal is to assess the safety, tolerability, and clinical and metabolic benefits of the treatment compared to placebo.PR NewswireMaggie's Pearl Initiates Phase III Clinical Trial for Treatment of Patients with PMM2-CDGMaggie's Pearl, a joint venture between Perlara, Maggie's Cure, and the Mayo Clinic, has initiated a Phase III clinical trial evaluating oral epalrestat therapy for pediatric patients with PMM2-CDG, a rare genetic disorder affecting approximately 1,000 people worldwide. The randomized, double-blind, placebo-controlled study, approved by the FDA in December 2021, is actively recruiting 40 patients with the first two subjects dosed in December 2022. If successful, the trial could provide the first viable treatment option for children living with this potentially fatal disease.BioPharma DivePerlara CEO Ethan Perlstein on reviving a biotech and building a ‘Y Combinator of rare diseases’Perlara CEO Ethan Perlstein is reviving the biotechnology company to act as an accelerator for rare disease treatments, partnering with patient-led startups like Maggie’s Pearl to repurpose existing drugs. The company has achieved near breakeven status through a decentralized research model and is preparing to launch several new spinouts focused on off-label drug uses.Business InsiderThe buzzy biotech Perlara got into Y Combinator and raised $10 million from investors like Mark Cuban before things went south. Its founder shares the key lesson he learned from the failure.Perlara, a biotech startup founded by Ethan Perlstein, is winding down operations after failing to secure additional funding following the departure of a key partner in January 2019. The company had previously raised $10 million from investors including Mark Cuban and Novartis, which also formed a research partnership with Perlara. Perlstein attributes the failure to rapid growth and a corporate structure that may have deterred new investors.PR NewswirePerlara announces APOL1 kidney disease PerlQuest partnership with Rambam Medical CenterPerlara, a rare diseases biotech public benefit corporation based in South San Francisco, announced a PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of Dr. Karl Skorecki to discover treatments for APOL1 kidney disease. Under the partnership, Perlara will adapt Dr. Skorecki's APOL1 G1 and G2 risk allele fly models and engineer nematode models to screen its drug repurposing library for approved drugs that rescue disease phenotypes. The genetic risk for APOL1 kidney disease affects approximately 100 million people worldwide, with no therapeutic approach currently available beyond dialysis and kidney transplants.The Dallas Morning NewsMcKinney boy's story moves Mark Cuban to invest in research targeting ultra-rare, fatal diseaseMark Cuban invested in San Francisco-based Perlara to develop treatments for Leigh syndrome, a fatal ultra-rare disease affecting 6-year-old Will Woleben. The company will screen and engineer drug compounds, aiming to lower costs and speed availability. Cuban's investment is estimated between $250,000 and $750,000.